300 related articles for article (PubMed ID: 31216825)
21. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
23. Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children.
Xi X; Liu JM; Guo JY
Int Arch Allergy Immunol; 2018; 176(3-4):255-267. PubMed ID: 29874664
[TBL] [Abstract][Full Text] [Related]
24. New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract][Full Text] [Related]
25. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
27. The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Chen JX; Yi XJ; Gao SX; Sun JX
Gen Physiol Biophys; 2020 Jul; 39(4):319-330. PubMed ID: 32902402
[TBL] [Abstract][Full Text] [Related]
28. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
29. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
30. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
32. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
[TBL] [Abstract][Full Text] [Related]
33. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
34. Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma.
Ju F; Wang D; Huang L; Jiang C; Gao C; Xiong C; Zhai G
Front Immunol; 2023; 14():1227756. PubMed ID: 37545535
[TBL] [Abstract][Full Text] [Related]
35. [The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis].
Piętak P; Pietrzyk N; Pawłowska A; Suszczyk D; Bednarek W; Kotarski J; Wertel I
Wiad Lek; 2018; 71(5):1089-1094. PubMed ID: 30176647
[TBL] [Abstract][Full Text] [Related]
36. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Xue S; Hu M; Iyer V; Yu J
J Hematol Oncol; 2017 Apr; 10(1):81. PubMed ID: 28388955
[TBL] [Abstract][Full Text] [Related]
37. Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Liu SY; Wu YL
J Hematol Oncol; 2017 Jul; 10(1):136. PubMed ID: 28679395
[TBL] [Abstract][Full Text] [Related]
38. [Role of programmed death-1 in viral infectious diseases].
Lu FC; Nong GM
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Jan; 20(1):77-82. PubMed ID: 29335088
[TBL] [Abstract][Full Text] [Related]
39. Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases.
Wang X; Wu M; Cao Y; Zhang Z; Guo F; Li X; Zhang Y
Crit Rev Clin Lab Sci; 2019 Jan; 56(1):18-32. PubMed ID: 30602320
[TBL] [Abstract][Full Text] [Related]
40. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
